Lutein and zeaxanthin
Also called: lutein, zeaxanthin, lutein/zeaxanthin
Lutein and zeaxanthin are carotenoids that the body does not convert into vitamin A; they accumulate in the retina. EFSA's evaluation of lutein as a food additive covers lutein extracted from marigold (Tagetes erecta).
- Category
- Other
- Forms
- Lutein and zeaxanthin (AREDS2 used lutein 10 mg plus zeaxanthin 2 mg); EFSA's food-additive evaluation covers lutein from Tagetes erecta
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 2 Moderately studied in people. A 2022 meta-analysis pooled three RCTs (406 preterm infants) of oral lutein/zeaxanthin versus placebo, and AREDS2 randomized lutein 10 mg + zeaxanthin 2 mg versus placebo. A 2014 five-RCT meta-analysis was not counted: its abstract does not show that each trial gave lutein alone. [8]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep1 topic
CPregnancy and infants1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Progression to advanced age-related macular degeneration (AMD), added to the AREDS formulation | X | AREDS2 (4,203 people aged 50–85 at risk of advanced AMD; median 5 years): adding lutein 10 mg + zeaxanthin 2 mg to the AREDS formulation did not further reduce risk of progression to advanced AMD in primary analyses (HR 0.90). [3] |
| Lutein/zeaxanthin in place of beta-carotene in the AREDS formulation | C | In 10-year AREDS2 follow-up (3,882 participants), an epidemiologic study, lutein/zeaxanthin versus beta carotene had HR 0.85 for late AMD; beta carotene had been replaced by lutein/zeaxanthin in the revised supplement. [4] |
| Macular pigment optical density and visual acuity in people with or at risk of AMD | B | A meta-analysis of five RCTs (445 participants) found lutein raised macular pigment optical density and gave a milder improvement in visual acuity versus placebo; the authors said the number of studies was not adequate for conclusive evidence. [5] |
| Cataract surgery and vision loss | X | In AREDS2 (3,159 participants with a natural lens, median 4.7 years), lutein/zeaxanthin had no statistically significant overall effect on cataract surgery (HR 0.96) or vision loss. [6] |
| Cognitive function in adults | C | A 2021 meta-analysis of seven RCTs (five lutein/zeaxanthin supplement trials, two avocado trials) found no significant effect of lutein on complex attention, executive function or memory. [7] |
| Retinopathy of prematurity in preterm infants | C | Three RCTs (406 preterm infants) of oral lutein/zeaxanthin versus placebo failed to show any reduction in retinopathy of prematurity, bronchopulmonary dysplasia, sepsis, NEC or mortality. [8] |
Main constituents: Lutein and zeaxanthin, non-provitamin A carotenoids that accumulate in the retina [1]; Tagetes erecta lutein preparation: at least 80% carotenoids, of which about 79% lutein and about 5% zeaxanthin [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- AREDS2: lutein 10 mg plus zeaxanthin 2 mg daily (median follow-up 5 years). [3]
- AREDS2 formulation: vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, copper (cupric oxide) 2 mg, lutein 10 mg and zeaxanthin 2 mg; it contains no beta-carotene. [9]
- In a meta-analysis of AMD trials, a daily dose of 10 mg lutein was as effective as higher doses. [5]
Upper limits
- EFSA (2010) set an acceptable daily intake (ADI) of 1 mg/kg body weight per day for lutein from Tagetes erecta used as a food additive (E 161b). [2]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In AREDS2 10-year follow-up, lung cancer odds were not significantly raised for lutein/zeaxanthin (OR 1.15) but were for beta carotene (OR 1.82). [4]
- NEI: former smokers who took a formulation with beta-carotene had a higher incidence of lung cancer; NEI states that current and former smokers should take the AREDS2 formula and avoid the AREDS formula with beta-carotene. [9]
- EFSA based its ADI on a no-observed-adverse-effect level of 200 mg/kg bw/day in a 90-day rat study, with no developmental toxicity up to 1000 mg/kg bw/day and no genotoxicity. [2]
Regulatory status
- EU: EFSA re-evaluated lutein (E 161b) as a food additive in 2010 and set an ADI of 1 mg/kg bw/day. [2]
- US: No NDI notification naming lutein was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). The list has 3 entries naming zeaxanthin (earliest NDI 90 submitted 2000-08-08; most recent NDI 325 submitted 2005-04-08). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [10]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [11]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Lutein and zeaxanthin (non-provitamin A carotenoids that accumulate in the retina) Carotenoids (xanthophylls) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming lutein was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). The list has 3 entries naming zeaxanthin (earliest NDI 90 submitted 2000-08-08; most recent NDI 325 submitted 2005-04-08). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of lutein or zeaxanthin was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- EFSA's lutein (E 161b) evaluation covers lutein from Tagetes erecta (marigold) containing at least 80% carotenoids. [P5]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- NIH Office of Dietary Supplements. Vitamin A and Carotenoids: Fact Sheet for Health Professionals (Updated March 10, 2025), 2025-03-10. ods.od.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- EFSA ANS Panel. Scientific Opinion on the re-evaluation of lutein (E 161b) as a food additive. EFSA Journal 2010;8(7):1678 (published 28 July 2010), 2010-07-28. efsa.europa.eu
Sources
- NIH Office of Dietary Supplements. Vitamin A and Carotenoids: Fact Sheet for Health Professionals (Updated March 10, 2025), 2025-03-10. ods.od.nih.gov
- EFSA ANS Panel. Scientific Opinion on the re-evaluation of lutein (E 161b) as a food additive. EFSA Journal 2010;8(7):1678 (published 28 July 2010), 2010-07-28. efsa.europa.eu
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA 2013;309(19):2005-15 (PMID 23644932), 2013-05-15. pubmed.ncbi.nlm.nih.gov
- Chew EY, et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28. JAMA Ophthalmol 2022;140(7):692-698 (PMID 35653117), 2022-07-01. pubmed.ncbi.nlm.nih.gov
- Wang X, et al. Role of lutein supplementation in the management of age-related macular degeneration: meta-analysis of randomized controlled trials. Ophthalmic Res 2014;52(4):198-205 (PMID 25358528), 2014. pubmed.ncbi.nlm.nih.gov
- AREDS2 Research Group. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol 2013;131(7):843-50 (PMID 23645227), 2013-07. pubmed.ncbi.nlm.nih.gov
- Li J, Abdel-Aal EM. Dietary lutein and cognitive function in adults: a meta-analysis of randomized controlled trials. Molecules 2021;26(19):5794 (PMID 34641336), 2021-09-24. pubmed.ncbi.nlm.nih.gov
- Cota F, et al. Lutein supplementation and retinopathy of prematurity: a meta-analysis. J Matern Fetal Neonatal Med 2022;35(1):175-180 (PMID 32041442), 2022-01. pubmed.ncbi.nlm.nih.gov
- National Eye Institute (NIH). Age-Related Eye Disease Studies (AREDS/AREDS2): major findings (no update date printed; accessed 2026-10-29), 2026-10-29. nei.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.